2018
DOI: 10.1080/16066359.2018.1508568
|View full text |Cite
|
Sign up to set email alerts
|

Stigma, problem drug use, and welfare state encounters: changing contours of stigmatization in the era of social investment

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
3
0

Year Published

2020
2020
2023
2023

Publication Types

Select...
5
1

Relationship

0
6

Authors

Journals

citations
Cited by 6 publications
(3 citation statements)
references
References 42 publications
0
3
0
Order By: Relevance
“…In accordance with socioecological models, stigmatising public attitudes are reinforced by (drug) policy, laws, societal structures, and the media, and may be reproduced through the practices of some institutions and professionals (da Silveira et al, 2018;Gilchrist et al, 2011;Russell et al, 2011;Skinner et al, 2007;Soh et al, 2019;Stangl et al, 2019;van Boekel et al, 2013;von Hippel et al, 2008). This can undermine provision, access, and the quality of drug treatment, and may reinforce discrimination and broader health and social inequity (Andersen & Kessing, 2019;Lancaster et al, 2017;Rivera et al, 2014;Smith et al, 2016). People who use drugs (PWUD), including those in receipt of treatment, report that perceptions and experiences of public and internalised stigma can lead to reduced self-worth and label avoidance, and act as a barrier to treatment seeking and recovery (Biancarelli et al, 2019;Birtel et al, 2017;Chan Carusone et al, 2019;Luoma et al, 2007;Neale et al, 2011;Stringer & Baker, 2018).…”
Section: Introductionmentioning
confidence: 99%
“…In accordance with socioecological models, stigmatising public attitudes are reinforced by (drug) policy, laws, societal structures, and the media, and may be reproduced through the practices of some institutions and professionals (da Silveira et al, 2018;Gilchrist et al, 2011;Russell et al, 2011;Skinner et al, 2007;Soh et al, 2019;Stangl et al, 2019;van Boekel et al, 2013;von Hippel et al, 2008). This can undermine provision, access, and the quality of drug treatment, and may reinforce discrimination and broader health and social inequity (Andersen & Kessing, 2019;Lancaster et al, 2017;Rivera et al, 2014;Smith et al, 2016). People who use drugs (PWUD), including those in receipt of treatment, report that perceptions and experiences of public and internalised stigma can lead to reduced self-worth and label avoidance, and act as a barrier to treatment seeking and recovery (Biancarelli et al, 2019;Birtel et al, 2017;Chan Carusone et al, 2019;Luoma et al, 2007;Neale et al, 2011;Stringer & Baker, 2018).…”
Section: Introductionmentioning
confidence: 99%
“…It also assumes that service users can easily evaluate services and make a rational decision about a range of treatment options. However, this overlooks the fact that the service user may be disadvantaged, may not be educated about addiction or may face other challenges which could prevent them from wanting to engage with a service, such as homelessness or access to services (Lancaster et al, 2015;Whiteford et al, 2016;Andersen and Kessing, 2018;Lucas et al, 2018).…”
Section: A Problem Of Product Qualitymentioning
confidence: 99%
“…Public stigma and internalisation of negative attitudes by labelled groups (i.e. self-stigma) is associated with reduced health and social care uptake, poorer quality of care and outcomes, and reduced public support for supportive policies and services (Rivera et al , 2014; Lancaster et al , 2017; Andersen and Kessing, 2019). Negative outcomes can affect others such as family members of out-groups through processes of association (Dyregrov and Selseng, 2021), and this may also be internalised as affiliate stigma (Mak and Cheung, 2008), leading to concealment, isolation and reductions in quality of life (Marshall, 2013).…”
Section: Introductionmentioning
confidence: 99%